Everest Medicines
EVM18 delivers CD19 CAR mRNA in targeted LNPs. Everest’s 2026 interim results report IIT initiation in autoimmune disease and global IND preparation. EVM14 and EVM16 are cancer vaccines, not its in vivo CAR-T lead.
Corporate information
- Company entity
- Everest Medicines
- Headquarters / principal office
- Hongkou District, Shanghai, China ↗
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly traded (HKEX: 1952); public-market transactions tracked separately ↗
- Official corporate reference
- https://everestmedicines.com/product-science/pipeline-and-major-products ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
EVM18 delivers CD19 CAR mRNA in targeted LNPs. Everest’s 2026 interim results report IIT initiation in autoimmune disease and global IND preparation. EVM14 and EVM16 are cancer vaccines, not its in vivo CAR-T lead.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Everest Medicines — official page checked
- Everest Medicines — supporting primary disclosure
- Corporate headquarters disclosure
- Corporate ownership / financing disclosure